ATE205704T1 - ORAL MODIFIED RELEASE DRUG CONTAINING 5-ASA AND METHOD FOR TREATING INTESTINAL DISEASES - Google Patents

ORAL MODIFIED RELEASE DRUG CONTAINING 5-ASA AND METHOD FOR TREATING INTESTINAL DISEASES

Info

Publication number
ATE205704T1
ATE205704T1 AT96943884T AT96943884T ATE205704T1 AT E205704 T1 ATE205704 T1 AT E205704T1 AT 96943884 T AT96943884 T AT 96943884T AT 96943884 T AT96943884 T AT 96943884T AT E205704 T1 ATE205704 T1 AT E205704T1
Authority
AT
Austria
Prior art keywords
asa
modified release
drug containing
release drug
intestinal diseases
Prior art date
Application number
AT96943884T
Other languages
German (de)
Inventor
Svenn Kluever Jepsen
Soeren Halskov
Original Assignee
Ferring Farma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24302375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE205704(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Farma Lab filed Critical Ferring Farma Lab
Application granted granted Critical
Publication of ATE205704T1 publication Critical patent/ATE205704T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

Modified release pharmaceutical composition and method for the treatment of inflammatory bowel diseases (IBD) such as Crohn's disease and Colitis Ulcerosa, said compositions comprising as active the ingredient 5-aminosalicyclic acid (5-ASA), and being adapted for modified and targeted release so as to obtain a clinically important localized effect profile of 5-ASA by means of releasing an appropriate amount of 5-ASA in both the small and large bowel.
AT96943884T 1995-12-21 1996-12-23 ORAL MODIFIED RELEASE DRUG CONTAINING 5-ASA AND METHOD FOR TREATING INTESTINAL DISEASES ATE205704T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57595495A 1995-12-21 1995-12-21
PCT/DK1996/000551 WO1997023199A1 (en) 1995-12-21 1996-12-23 Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases

Publications (1)

Publication Number Publication Date
ATE205704T1 true ATE205704T1 (en) 2001-10-15

Family

ID=24302375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96943884T ATE205704T1 (en) 1995-12-21 1996-12-23 ORAL MODIFIED RELEASE DRUG CONTAINING 5-ASA AND METHOD FOR TREATING INTESTINAL DISEASES

Country Status (28)

Country Link
EP (1) EP0871434B2 (en)
JP (1) JP4714836B2 (en)
KR (2) KR100598714B1 (en)
CN (1) CN1155369C (en)
AT (1) ATE205704T1 (en)
AU (1) AU702934B2 (en)
BG (1) BG63484B1 (en)
BR (1) BR9612213A (en)
CA (1) CA2240281C (en)
CZ (1) CZ289290B6 (en)
DE (2) DE871434T1 (en)
DK (1) DK0871434T4 (en)
EE (1) EE03740B1 (en)
ES (1) ES2149733T5 (en)
HK (1) HK1017615A1 (en)
HU (1) HU228856B1 (en)
IL (1) IL124858A (en)
IS (1) IS1834B (en)
NO (1) NO320498B1 (en)
NZ (1) NZ325201A (en)
PL (1) PL186790B1 (en)
PT (1) PT871434E (en)
RU (1) RU2181043C2 (en)
SI (1) SI0871434T2 (en)
SK (1) SK282669B6 (en)
TR (1) TR199801158T2 (en)
UA (1) UA67721C2 (en)
WO (1) WO1997023199A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19732903A1 (en) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
MXPA01007463A (en) 1999-01-29 2002-06-04 Losan Pharma Gmbh Pharmaceutical compositions.
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
WO2003032952A1 (en) * 2001-10-15 2003-04-24 Ferring Bv Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease
AR036797A1 (en) 2001-10-15 2004-10-06 Ferring Bv A METHOD TO PREPARE A PHARMACEUTICAL COMPOSITION THAT INCLUDES 5-AMINOSALICILIC ACID TO USE IN THE TREATMENT OF ULCEROSE COLITIS AND CROHN DISEASES
JP2007523664A (en) * 2003-04-23 2007-08-23 フェリング ベスローテン フェンノートシャップ Sachet for pharmaceutical composition
EP1547601A1 (en) * 2003-12-23 2005-06-29 Ferring B.V. Coating method
RU2297835C1 (en) 2005-09-26 2007-04-27 Закрытое акционерное общество "Партнер" Preparation for treatment of noninfectious inflammatory intestine diseases
JP5450053B2 (en) * 2006-04-13 2014-03-26 ニューロテック ファーマシューティカルズ カンパニー リミテッド Pharmaceutical composition for treating or preventing cell damage and inflammatory diseases
JP2012500786A (en) * 2008-08-22 2012-01-12 レキット ベンキサー ヘルスケア （ユーケイ） リミテッド Improvements in or related to the composition
CN102238868A (en) 2008-10-03 2011-11-09 福尔克博士药物有限责任公司 Compositions and methods for the treatment of bowel diseases with granulated mesalamine
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
RU2463055C2 (en) * 2011-01-12 2012-10-10 Петр Леонидович Щербаков Method of treating inflammatory intestinal diseases
CN102319218B (en) * 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 Drug sustained and controlled release microparticle preparation for treating intestinal diseases, and preparation method thereof
US20150164920A1 (en) 2012-03-30 2015-06-18 Laboratorios Del Dr. Esteve S.A. Controlled release formulation comprising mesalamine
RU2752082C1 (en) * 2020-09-29 2021-07-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Product with granules containing 5-aminosalicylic acid and folic acid with controlled release

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (en) * 1980-03-20 1982-03-11
SE457505B (en) * 1984-01-10 1989-01-09 Lejus Medical Ab LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IT1246382B (en) * 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON

Also Published As

Publication number Publication date
KR100542544B1 (en) 2006-05-10
HUP0001084A3 (en) 2000-12-28
HK1017615A1 (en) 1999-11-26
WO1997023199A1 (en) 1997-07-03
DE871434T1 (en) 2001-04-05
CA2240281A1 (en) 1997-07-03
NO982904D0 (en) 1998-06-22
CZ289290B6 (en) 2001-12-12
JP4714836B2 (en) 2011-06-29
NO320498B1 (en) 2005-12-12
KR19990076584A (en) 1999-10-15
DE69615400T2 (en) 2002-05-23
CN1207672A (en) 1999-02-10
ES2149733T1 (en) 2000-11-16
JPH11510191A (en) 1999-09-07
RU2181043C2 (en) 2002-04-10
UA67721C2 (en) 2004-07-15
CA2240281C (en) 2007-02-27
HUP0001084A2 (en) 2000-11-28
CZ194698A3 (en) 1998-10-14
SK83498A3 (en) 1999-01-11
DE69615400T3 (en) 2008-08-07
BR9612213A (en) 1999-12-28
TR199801158T2 (en) 1998-09-21
ES2149733T5 (en) 2008-05-01
PL327323A1 (en) 1998-12-07
PL186790B1 (en) 2004-02-27
HU228856B1 (en) 2013-06-28
BG63484B1 (en) 2002-03-29
AU1366197A (en) 1997-07-17
KR20050087886A (en) 2005-08-31
BG102556A (en) 1999-02-26
DK0871434T3 (en) 2002-01-07
DE69615400D1 (en) 2001-10-25
SI0871434T2 (en) 2008-04-30
NO982904L (en) 1998-06-22
PT871434E (en) 2002-02-28
NZ325201A (en) 1998-11-25
IS4772A (en) 1998-06-15
SK282669B6 (en) 2002-11-06
CN1155369C (en) 2004-06-30
EP0871434A1 (en) 1998-10-21
ES2149733T3 (en) 2002-04-01
EP0871434B2 (en) 2007-12-12
KR100598714B1 (en) 2006-07-10
AU702934B2 (en) 1999-03-11
EE9800191A (en) 1998-12-15
SI0871434T1 (en) 2002-04-30
IL124858A (en) 2003-03-12
EE03740B1 (en) 2002-06-17
EP0871434B1 (en) 2001-09-19
DK0871434T4 (en) 2008-04-07
IL124858A0 (en) 1999-01-26
IS1834B (en) 2002-11-15

Similar Documents

Publication Publication Date Title
ATE205704T1 (en) ORAL MODIFIED RELEASE DRUG CONTAINING 5-ASA AND METHOD FOR TREATING INTESTINAL DISEASES
RU95109905A (en) Liquid, semisolid, solid, gel-like or paste-like compositions and a method of mouth cavity disease treatment
DE69720985D1 (en) ADMINISTRATION OF nicotine in the large intestine for the treatment of inflammatory bowel disease
DE69634693D1 (en) MULTIPLE UNSATURATED OMEGA-3 FATTY ACIDS FOR THE TREATMENT OF INFLAMMATORY ENDURANCE DISEASES IN CAPSULES WITH TIME DEPENDENT RELEASE
DE69629797D1 (en) MATRIX FOR CONTROLLED RELEASE OF MEDICINAL PRODUCTS
DE69634776D1 (en) USE OF AN R-NSAID AS A CHEMICAL PROTECTION AGENT FOR THE TREATMENT OF COLORECTAL CANCER
ATE129893T1 (en) ORAL DOSAGE FORM WITH DELAYED RELEASE FOR THE TREATMENT OF INTESTINAL DISEASES.
EA199600028A2 (en) Oral formulations of S(+)-ibuprofen
DE69021214D1 (en) ORAL COMPOSITION FOR THE TREATMENT OF INTESTINAL FLAMMABLE DISEASES.
DE69025271D1 (en) Delayed release pharmaceutical preparations for the treatment of periodontal diseases
DK0497956T3 (en) Controlled release preparations
ATE265851T1 (en) TREATMENT OF DISEASES CAUSED BY CYTOKINE GROWTH FACTOR
ATE15897T1 (en) STARTING PRODUCTS FOR THE MANUFACTURE OF CEPHALOSPORINS AND PROCESS FOR THEIR MANUFACTURE.
DE69634080D1 (en) MEANS OF PREVENTING THE TURNING OF THE FRONT LENS CAPSULE
ATE12649T1 (en) OPTICALLY ACTIVE DIPEPTIDE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, METHOD OF PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
IL110888A (en) Pharmaceutical compositions for the treatment of liver diseases comprising a vasodilating compound
TH43680A (en) Chertaline salt and sertraline-delayed use patterns

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0871434

Country of ref document: EP